GLSI - Greenwich LifeSciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Stafford,
United States
Type: Equity
GLSI price evolution
GLSI
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.82 | $7.22 | $5.51 | $6.99 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $5.82 | $7.23 | $5.51 | $6.99 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | $0 | $0 | $0.01 | |
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $5.83 | $7.23 | $5.51 | $6.99 |
| Current liabilities | ||||
| Accounts payable | $0.77 | $1.34 | $0.35 | $0.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.84 | $1.35 | $0.39 | $0.29 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.84 | $1.35 | $0.39 | $0.29 |
| Shareholders' equity | ||||
| Retained earnings | -$58.11 | -$55.44 | -$52.84 | -$50.36 |
| Other shareholder equity | ||||
| Total shareholder equity | $5.88 | $5.12 | $6.7 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.99 | $13.47 | $27.2 | $28.66 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $6.99 | $13.48 | $27.22 | $28.66 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | $0.01 | $0.01 | $0.01 | $0.02 |
| Total noncurrent assets | $0.02 | |||
| Total investments | ||||
| Total assets | $6.99 | $13.48 | $27.22 | $28.68 |
| Current liabilities | ||||
| Accounts payable | $0.26 | $0.22 | $0.22 | $0.71 |
| Deferred revenue | ||||
| Short long term debt | $0.28 | |||
| Total current liabilities | $0.29 | $0.26 | $0.39 | $1.05 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.28 | |||
| Total liabilities | $0.29 | $0.26 | $0.39 | $1.05 |
| Shareholders' equity | ||||
| Retained earnings | -$50.36 | -$41.47 | -$33.65 | -$29.08 |
| Other shareholder equity | ||||
| Total shareholder equity | $6.7 | $13.21 | $26.83 | $27.63 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.31 | $2.19 | $2.33 | |
| Selling, general & administrative | $0.35 | $0.34 | $0.5 | |
| Total operating expenses | $2.73 | $2.66 | $2.54 | $2.84 |
| Operating income | -$2.66 | -$2.54 | -$2.84 | |
| Income from continuing operations | ||||
| EBIT | -$2.61 | -$2.47 | -$2.75 | |
| Income tax expense | ||||
| Interest expense | $0.06 | |||
| Net income | ||||
| Net income | -$2.67 | -$2.61 | -$2.47 | -$2.75 |
| Income (for common shares) | -$2.61 | -$2.47 | -$2.75 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.7 | $6.48 | $3.56 | $1.06 |
| Selling, general & administrative | $1.63 | $1.56 | $1.04 | $0.81 |
| Total operating expenses | $9.33 | $8.04 | $4.6 | $1.86 |
| Operating income | -$9.33 | -$8.04 | -$4.6 | -$1.86 |
| Income from continuing operations | ||||
| EBIT | -$8.89 | -$7.83 | -$4.57 | -$1.86 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.89 | -$7.83 | -$4.57 | -$1.86 |
| Income (for common shares) | -$8.89 | -$7.83 | -$4.57 | -$1.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$2.61 | -$2.47 | -$2.75 | |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.59 | $0.59 | $0.59 | |
| Total cash flows from operations | -$1.05 | -$1.78 | -$2.15 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.77 | $0.3 | ||
| Net borrowings | ||||
| Total cash flows from financing | $4.25 | $2.77 | $0.3 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.17 | $1.72 | -$1.48 | -$2.15 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$8.89 | -$7.83 | -$4.57 | -$1.86 |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.38 | $1.74 | $0.66 | $0.68 |
| Total cash flows from operations | -$6.48 | -$6.2 | -$4.29 | -$1.15 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$7.54 | $3.11 | $30.17 | |
| Net borrowings | -$0.28 | -$0.36 | ||
| Total cash flows from financing | -$7.54 | $2.84 | $29.81 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.48 | -$13.74 | -$1.46 | $28.65 |
News
Fundamentals
| Market cap | $131.32M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.14M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$10.50M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -12.51 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.44 |
| EPS | -$0.80 |
|---|---|
| ROA | -164.25% |
| ROE | N/A |
| Debt/Equity | 0.04 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.91 |
| Quick ratio | N/A |